← Leaderboards
Juan C Vasquez
Yale University
$1,156,265
Attributed
$1,156,265
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $231.3K · FY2021–25$250K$187.5K$125K$62.5K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,156,265 · 1
By mechanism
K08$1,156,265 · 1
Top collaborators
No co-investigators on record.
Most similar at Yale University
Same institution · by research overlap
- Harriet M Kluger$18,066,555
- Peter M Glazer$37,467,142
- David F Stern$15,325,663
- Eric P Winer$9,445,197
- Ranjit Bindra$5,884,099
Others in their field
Other Emerging Leaders on “Dna Repair”
- Russell T Hepple · California Pacific Med Ctr Res Institute$6,127,391
- Chongyuan Luo · University Of California Los Angeles$5,685,803
- William Raymond Lagor · Baylor College Of Medicine$5,351,429
- Samuel Henry Sternberg · Columbia University Health Sciences$5,236,150
- James M Dewar · Vanderbilt University$4,949,419
- William H. Peranteau · Children'S Hosp Of Philadelphia$4,881,032
Research focus
Dna RepairDouble Strand Break RepairAnti-Pd1 TherapyAdvisory CommitteesDna Repair PathwayCancer BiologyCancer CellCancer TherapyAtr GeneCell Cycle ProgressionCell PhysiologyBrca DeficientCheckpoint InhibitionCitric Acid CycleClinical EfficacyClinical Trials DesignComparative EfficacyComputational BiologyCytotoxicityDefectDioxygenasesDna DamageDna Double Strand BreakEarly Phase Clinical Trial
Grant awards (5)
Targeting the DNA damage response with PARP and ATR inhibition to potentiate cytotoxicity and improve efficacy of immune checkpoint blockade in IDH mutant gliomas$231,253
K08 · FY2025 · CA · contact PI
Targeting the DNA damage response with PARP and ATR inhibition to potentiate cytotoxicity and improve efficacy of immune checkpoint blockade in IDH mutant gliomas$231,253
K08 · FY2024 · CA · contact PI
Targeting the DNA damage response with PARP and ATR inhibition to potentiate cytotoxicity and improve efficacy of immune checkpoint blockade in IDH mutant gliomas$231,253
K08 · FY2023 · CA · contact PI
Targeting the DNA damage response with PARP and ATR inhibition to potentiate cytotoxicity and improve efficacy of immune checkpoint blockade in IDH mutant gliomas$231,253
K08 · FY2022 · CA · contact PI
Targeting the DNA damage response with PARP and ATR inhibition to potentiate cytotoxicity and improve efficacy of immune checkpoint blockade in IDH mutant gliomas$231,253
K08 · FY2021 · CA · contact PI